载药栓塞微球TACE联合阿帕替尼及卡瑞利珠单抗治疗巨块型肝细胞癌  

Drug-eluting bead TACE combined with apatinib and camrelizumab for treating massive hepatocellular carcinoma

作　　者：陈金威 任建庄[1] 段旭华[1] 陈鹏飞[1] 朱兴书 CHEN Jinwei;REN Jianzhuang;DUAN X uhua;CHEN Pengfei;ZHU Xingshu(Department of Interventional Radiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院放射介入科,河南郑州450052

出　　处：《中国介入影像与治疗学》2024年第2期65-69,共5页Chinese Journal of Interventional Imaging and Therapy

基　　金：2019年河南省医学科技攻关计划联合共建项目(LHGJ20190163)。

摘　　要：目的 观察载药栓塞微球TACE(D-TACE)联合阿帕替尼和卡瑞利珠单抗治疗巨块型肝细胞癌(HCC)的价值。方法 回顾性分析35例接受D-TACE序贯阿帕替尼和卡瑞利珠单抗治疗的巨块型HCC患者资料,记录其总生存期(OS)和无进展生存期(PFS),评价客观反应率(ORR)、疾病控制率(DCR)及治疗相关不良事件(TRAE)。结果 35例联合治疗均成功。截止至末次随访,35例中位PFS为8.09个月,中位OS为20.00个月。联合治疗后1、3、6及12个月,ORR分别为65.71%(23/35)、71.43%(25/35)、65.71%(23/35)及60.71%(17/28),DCR分别为94.29%(33/35)、88.57%(31/35)、80.00%(28/35)及67.86%(19/28)。联合治疗TRAE主要为1~2级,均经对症处理后缓解。结论 D-TACE联合阿帕替尼和卡瑞利珠单抗治疗巨块型HCC效果较佳且安全,不良反应可控。Objective To observe the value of drug-eluting bead TACE(D-TACE)combined with apatinib and camrelizumab for treating massive hepatocellular carcinoma(HCC).Methods Data of 35 patients with massive HCC who underwent D-TACE sequential apatinib and camrelizumab were retrospectively analyzed.The overall survival(OS)and progression free survival(PFS)were recorded,and the objective response rate(ORR),disease control rate(DCR)and treatment-related adverse event(TRAE)were evaluated.Results Combination treatment were all successfully performed in all 35 cases.At the last follow-up,the median PFS was 8.09 months,and the median OS was 20.00 months.One,3,6,and 12 months after treatments,ORR was 65.71%(23/35),71.43%(25/35),65.71%(23/35)and 60.71%(17/28),respectively,DCR was 94.29%(33/35),88.57%(31/35),80.00%(28/35)and 67.86%(19/28),respectively.TRAE of combination treatment mainly ranged from grade 1 to 2,and all relieved after symptomatic treatments.Conclusion D-TACE combined with apatinib and camrelizumab was effective and safe for treating massive HCC,with controllable adverse reactions.

关 键 词：癌 肝细胞 化学栓塞 治疗性 阿帕替尼 卡瑞利珠单抗 

分 类 号：R737.5[医药卫生—肿瘤] R815[医药卫生—临床医学]